MedStar Authors catalog › Details for: A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design.
Normal view MARC view ISBD view

A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design.

by Lipinski, Michael J.
Citation: American Heart Journal. 177:66-73, 2016 Jul.Journal: American heart journal.Published: 2016ISSN: 0002-8703.Full author list: Zangrillo A; Alvaro G; Pisano A; Guarracino F; Lobreglio R; Bradic N; Lembo R; Gianni S; Calabro MG; Likhvantsev V; Grigoryev E; Buscaglia G; Pala G; Auci E; Amantea B; Monaco F; De Vuono G; Corcione A; Galdieri N; Cariello C; Bove T; Fominskiy E; Auriemma S; Baiocchi M; Bianchi A; Frontini M; Paternoster G; Sangalli F; Wang CY; Zucchetti MC; Biondi-Zoccai G; Gemma M; Lipinski MJ; Lomivorotov VV; Landoni G.UI/PMID: 27297851.Subject(s): Acute Kidney Injury/ep [Epidemiology] | Cardiac Output, Low/mo [Mortality] | *Cardiac Output, Low/th [Therapy] | Cardiac Surgical Procedures/mo [Mortality] | *Cardiotonic Agents/tu [Therapeutic Use] | Double-Blind Method | Humans | *Hydrazones/tu [Therapeutic Use] | Infusions, Intravenous | Intensive Care Units | *Intra-Aortic Balloon Pumping | Length of Stay/sn [Statistics & Numerical Data] | Postoperative Complications/mo [Mortality] | *Postoperative Complications/th [Therapy] | *Pyridazines/tu [Therapeutic Use] | Respiration, ArtificialInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.ahj.2016.03.021 (Click here) Abbreviated citation: Am Heart J. 177:66-73, 2016 Jul.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006.Abstract: OBJECTIVE: Patients undergoing cardiac surgery are at risk of perioperative low cardiac output syndrome due to postoperative myocardial dysfunction. Myocardial dysfunction in patients undergoing cardiac surgery is a potential indication for the use of levosimendan, a calcium sensitizer with 3 beneficial cardiovascular effects (inotropic, vasodilatory, and anti-inflammatory), which appears effective in improving clinically relevant outcomes.Abstract: DESIGN: Double-blind, placebo-controlled, multicenter randomized trial.Abstract: SETTING: Tertiary care hospitals.Abstract: INTERVENTIONS: Cardiac surgery patients (n = 1,000) with postoperative myocardial dysfunction (defined as patients with intraaortic balloon pump and/or high-dose standard inotropic support) will be randomized to receive a continuous infusion of either levosimendan (0.05-0.2 mug/[kg min]) or placebo for 24-48 hours.Abstract: MEASUREMENTS AND MAIN RESULTS: The primary end point will be 30-day mortality. Secondary end points will be mortality at 1 year, time on mechanical ventilation, acute kidney injury, decision to stop the study drug due to adverse events or to start open-label levosimendan, and length of intensive care unit and hospital stay. We will test the hypothesis that levosimendan reduces 30-day mortality in cardiac surgery patients with postoperative myocardial dysfunction.Abstract: CONCLUSIONS: This trial is planned to determine whether levosimendan could improve survival in patients with postoperative low cardiac output syndrome. The results of this double-blind, placebo-controlled randomized trial may provide important insights into the management of low cardiac output in cardiac surgery.Abstract: Copyright � 2016 Elsevier Inc. All rights reserved.

Powered by Koha